Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus

Journal of Virology

Volumn 82, Issue 21, 2008, Pages 10896-10905

  Youn, Jin Won ^a,h   Hu, Yu Wen ^b   Tricoche, Nancy ^a   Pfahler, Wolfram ^a,c   Shata, Mohamed Tarek ^d   Dreux, Marlene ^e   Cosset, François Loic ^e   Folgori, Antonella ^f   Lee, Dong Hun ^a,i   Brotman, Betsy ^a   Prince, Alfred M ^a,g  

^a NEW YORK BLOOD CENTER   (United States)

^b CANADIAN BLOOD SERVICES   (Canada)

^c Vilab II   (Liberia)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITÉ DE LYON   (France)

^f Okairòs ^*  (Italy)

^g Hepatitis Research Foundation   (United States)

^h Mogam Biotechnology Research Institute   (South Korea)

ⁱ Schering Plough   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA INTERFERON; VACCINIA VACCINE; VIRUS VECTOR; HEPATITIS C ANTIBODY; HEPATITIS VACCINE; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; PAN TROGLODYTES; SECRETION; T LYMPHOCYTE; VIREMIA; VIRUS LOAD;

ANIMALIA; HEPATITIS C VIRUS; PAN; VACCINIA VIRUS;

ANIMALS; ANTIGENS, VIRAL; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; PAN TROGLODYTES; T-LYMPHOCYTES; VACCINIA VIRUS; VIRAL HEPATITIS VACCINES; VIRAL LOAD; VIREMIA;

EID: 55249088800     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01179-08     Document Type: Article

References (72)

1. Abraham, J. D., N. Himoudi, F. Kien, J. L. Berland, A. Codran, B. Bartosch, T. Baumert, G. Paranhos-Baccala, C. Schuster, G. Inchauspe, and M. P. Kieny. 2004. Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 22:3917-3928.
2. + T cell population in chronic hepatitis C virus infection. J. Clin. Investig. 113:963-972.
3. Anonymous. 2008. A dozen good ideas to battle hepatitis. Lancet 371:1637.
4. Bartosch, B., J. Bukh, J. C. Meunier, C. Granier, R. E. Engle, W. C. Blackwelder, S. U. Emerson, F. L. Cosset, and R. H. Purcell. 2003. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. USA 100:14199-14204.
5. Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642.
6. Bartosch, B., G. Verney, M. Dreux, P. Donot, Y. Morice, F. Penin, J. M. Pawlotsky, D. Lavillette, and F. L. Cosset. 2005. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79:8217-8229.
7. Bennett, M. S., H. L. Ng, M. Dagarag, A. Ali, and O. O. Yang. 2007. Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J. Virol. 81:4973-4980.
8. + T cells during chronic hepatitis C virus infection. J. Virol. 79:7860-7867.
9. Bukh, J., R. H. Miller, and R. H. Purcell. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15:41-63.
10. + regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40:1062-1071.
11. Carreno, V. 2006. Occult hepatitis C virus infection: a new form of hepatitis C. World J. Gastroenterol. 12:6922-6925.
12. Chang, K. M., B. Rehermann, J. G. McHutchison, C. Pasquinelli, S. Southwood, A. Sette, and F. V. Chisari. 1997. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Investig. 100:2376-2385.
13. Choo, Q. L., G. Kuo, R. Ralston, A. Weiner, D. Chien, G. Van Nest, J. Han, K. Berger, K. Thudium, C. Kuo, et al. 1994. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA 91:1294-1298.
14. Cox, A. L., T. Mosbruger, Q. Mao, Z. Liu, X. H. Wang, H. C. Yang, J. Sidney, A. Sette, D. Pardoll, D. L. Thomas, and S. C. Ray. 2005. Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 201:1741-1752.
15. Davis, G. L., and J. Y. Lau. 1997. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26:122S-127S.
16. Donato, F., A. Tagger, R. Chiesa, M. L. Ribero, V. Tomasoni, M. Fasola, U. Gelatti, G. Portera, P. Boffetta, and G. Nardi. 1997. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 26:579-584.
17. Elmowalid, G. A., M. Qiao, S. H. Jeong, B. B. Borg, T. F. Baumert, R. K. Sapp, Z. Hu, K. Murthy, and T. J. Liang. 2007. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl. Acad. Sci. USA 104:8427-8432.
18. + T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine 23:58-68.
19. Fenner, F., D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladni. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
20. Folgori, A., S. Capone, L. Ruggeri, A. Meola, E. Sporeno, B. B. Ercole, M. Pezzanera, R. Tafi, M. Arcuri, E. Fattori, A. Lahm, A. Luzzago, A. Vitelli, S. Colloca, R. Cortese, and A. Nicosia. 2006. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12:190-197.
21. Forns, X., P. J. Payette, X. Ma, W. Satterfield, G. Eder, I. K. Mushahwar, S. Govindarajan, H. L. Davis, S. U. Emerson, R. H. Purcell, and J. Bukh. 2000. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32:618-625.
22. Gehring, S., S. H. Gregory, N. Kuzushita, and J. R. Wands. 2005. Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. J. Med. Virol. 75:249-257.
23. Gordon, E. J., R. Bhat, Q. Liu, Y. F. Wang, C. Tackney, and A. M. Prince. 2000. Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. J. Infect. Dis. 181:42-50.
24. + T lymphocytes after infection with hepatitis C virus. J. Virol. 75:5550-5558.
25. Hatzakis, A., A. Katsoulidou, E. Kaklamani, G. Touloumi, Y. Koumantaki, N. C. Tassopoulos, G. Karvountzis, A. Gioustozi, S. Hadziyannis, and D. Trichopoulos. 1996. Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: a case-control study. Int. J. Cancer 68:51-53.
26. Houghton, M., Q. L. Choo, D. Chien, G. Kuo, A. Weiner, S. Coates, et al. 1997. Development of an HCV vaccine, p. 656-659. In M. Rizzetto, R. H. Purcell, J. L. Gerin, and G. Verme (ed.), Viral hepatitits and liver disease. Edizioni Minerva Medica, Turin, Italy.
27. Hu, Y. W., E. Balaskas, M. Furione, P. H. Yen, G. Kessler, V. Scalia, L. Chui, and G. Sher. 2000. Comparison and application of a novel genotyping method, semiautomated primer-specific and mispair extension analysis, and four other genotyping assays for detection of hepatitis C virus mixed-genotype infections. J. Clin. Microbiol. 38:2807-2813.
28. Hu, Y. W., L. Rocheleau, B. Larke, L. Chui, B. Lee, M. Ma, S. Liu, T. Omlin, M. Pelchat, and E. G. Brown. 2005. Immunoglobulin mimicry by hepatitis C virus envelope protein E2. Virology 332:538-549.
29. Inchauspe, G., M. E. Major, I. Nakano, L. Vitvitski, and C. Trepo. 1997. DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 15:853-856.
30. Inchauspe, G., M. E. Major, I. Nakano, L. Vivitski, M. Maisonnas, and C. Trepo. 1998. Immune responses against hepatitis C virus structural proteins following genetic immunisation. Dev. Biol. Stand. 92:163-168.
31. Jeong, S. H., M. Qiao, M. Nascimbeni, Z. Hu, B. Rehermann, K. Murthy, and T. J. Liang. 2004. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J. Virol. 78:6995-7003.
32. Lanford, R. E., B. Guerra, D. Chavez, C. Bigger, K. M. Brasky, X. H. Wang, S. C. Ray, and D. L. Thomas. 2004. Cross-genotype immunity to hepatitis C virus. J. Virol. 78:1575-1581.
33. Laskus, T., L. F. Wang, J. Rakela, H. Vargas, A. D. Pinna, A. C. Tsamandas, A. J. Demetris, and J. Fung. 1996. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology 220:171-176.
34. Lee, D. H., and A. M. Prince. 2001. Automation of nucleic acid extraction for NAT screening of individual blood units. Transfusion 41:483-487.
35. Lee, S. W., J. H. Cho, K. J. Lee, and Y. C. Sung. 1998. Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Mol. Cell 8:444-451.
36. Lee, S. W., J. H. Cho, and Y. C. Sung. 1998. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J. Virol. 72:8430-8436.
37. Ma, X., X. Forns, R. Gutierrez, I. K. Mushahwar, T. Wu, P. J. Payette, J. Bukh, R. H. Purcell, and H. L. Davis. 2002. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine 20:3263-3271.
38. Major, M. E., L. Vitvitski, M. A. Mink, M. Schleef, R. G. Whalen, C. Trepo, and G. Inchauspe. 1995. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol. 69:5798-5805.
39. Makimura, M., S. Miyake, N. Akino, K. Takamori, Y. Matsuura, T. Miyamura, and I. Saito. 1996. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 14:28-36.
40. Matsui, M., O. Moriya, and T. Akatsuka. 2003. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 21:1629-1639.
41. Netter, H. J., T. B. Macnaughton, W. P. Woo, R. Tindle, and E. J. Gowans. 2001. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J. Virol. 75:2130-2141.
42. Neumann, A. U., N. P. Lam, H. Dahari, M. Davidian, T. E. Wiley, B. P. Mika, A. S. Perelson, and T. J. Layden. 2000. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182:28-35.
43. Pancholi, P., Q. Liu, N. Tricoche, P. Zhang, M. E. Perkus, and A. M. Prince. 2000. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J. Infect. Dis. 182:18-27.
44. Pancholi, P., M. Perkus, N. Tricoche, Q. Liu, and A. M. Prince. 2003. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J. Virol. 77:382-390.
45. Pardo, M., J. M. Lopez-Alcorocho, E. Rodriguez-Inigo, I. Castillo, and V. Carreno. 2007. Comparative study between occult hepatitis C virus infection and chronic hepatitis C. J. Viral Hepat. 14:36-40.
46. + T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 21:4555-4564.
47. Perkus, M. E., K. Limbach, and E. Paoletti. 1989. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J. Virol. 63:3829-3836.
48. Perkus, M. E., A. Piccini, B. R. Lipinskas, and E. Paoletti. 1985. Recombinant vaccinia virus: immunization against multiple pathogens. Science 229:981-984.
49. Prince, A. M., B. Brotman, D. H. Lee, W. Pfahler, N. Tricoche, L. Andrus, and M. T. Shata. 2005. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J. Infect. Dis. 192:1701-1709.
50. Puig, M., M. E. Major, K. Mihalik, and S. M. Feinstone. 2004. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22:991-1000.
51. Ray, S. C., L. Fanning, X. H. Wang, D. M. Netski, E. Kenny-Walsh, and D. L. Thomas. 2005. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J. Exp. Med. 201:1753-1759.
52. Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5:215-229.
53. Rollier, C., E. Depla, J. A. R. Drexhage, E. J. Verschoor, B. E. Verstrepen, A. Fatmi, C. Brinster, A. Fournillier, J. A. Whelan, M. Whelan, D. Jacobs, G. Maertens, G. Inchauspe, and J. L. Heeney. 2004. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol. 78:187-196.
54. Rollier, C. S., G. Paranhos-Baccala, E. J. Verschoor, B. E. Verstrepen, J. A. Drexhage, Z. Fagrouch, J. L. Berland, F. Komurian-Pradel, B. Duverger, N. Himoudi, C. Staib, M. Meyr, M. Whelan, J. A. Whelan, V. C. Adams, E. Larrea, J. I. Riezu, J. J. Lasarte, B. Bartosch, F. L. Cosset, W. J. Spaan, H. M. Diepolder, G. R. Pape, G. Sutter, G. Inchauspe, and J. L. Heeney. 2007. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45:602-613.
55. Seifert, U., H. Liermann, V. Racanelli, A. Halenius, M. Wiese, H. Wedemeyer, T. Ruppert, K. Rispeter, P. Henklein, A. Sijts, H. Hengel, P. M. Kloetzel, and B. Rehermann. 2004. Hepatitis C virus mutation affects proteasomal epitope processing. J. Clin. Investig. 114:250-259.
56. Shirai, M., M. Chen, T. Arichi, T. Masaki, M. Nishioka, M. Newman, T. Nakazawa, S. M. Feinstone, and J. A. Berzofsky. 1996. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J. Infect. Dis. 173:24-31.
57. Silini, E., R. Bottelli, M. Asti, S. Bruno, M. E. Candusso, S. Brambilla, F. Bono, G. Iamoni, C. Tinelli, M. U. Mondelli, and G. Ideo. 1996. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a casecontrol study. Gastroenterology 111:199-205.
58. Smith, G. L., and B. Moss. 1983. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25:21-28.
59. Song, M. K., S. W. Lee, Y. S. Suh, K. J. Lee, and Y. C. Sung. 2000. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J. Virol. 74:2920-2925.
60. + T-cell failure during chronic hepatitis C virus infection. Hepatology 42:828-837.
61. Stuyver, L., A. Wyseur, W. van Arnhem, F. Hernandez, and G. Maertens. 1996. Second-generation line probe assay for hepatitis C virus genotyping. J. Clin. Microbiol. 34:2259-2266.
62. Sugimoto, K., F. Ikeda, J. Stadanlick, F. A. Nunes, H. J. Alter, and K. M. Chang. 2003. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38:1437-1448.
63. Thimme, R., D. Oldach, K. M. Chang, C. Steiger, S. C. Ray, and F. V. Chisari. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194:1395-1406.
64. Timm, J., G. M. Lauer, D. G. Kavanagh, I. Sheridan, A. Y. Kim, M. Lucas, T. Pillay, K. Ouchi, L. L. Reyor, J. Schulze zur Wiesch, R. T. Gandhi, R. T. Chung, N. Bhardwaj, P. Klenerman, B. D. Walker, and T. M. Allen. 2004. CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med. 200:1593-1604.
65. Wedemeyer, H., E. Mizukoshi, A. R. Davis, J. R. Bennink, and B. Rehermann. 2001. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J. Virol. 75:11392-11400.
66. Wherry, E. J., J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911-4927.
67. Wuest, T., G. W. Both, A. M. Prince, C. Hofmann, and P. Loser. 2004. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 22:2717-2721.
68. Youn, J. W., S. H. Park, J. H. Cho, and Y. C. Sung. 2003. Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization. J. Virol. 77:11596-11602.
69. Youn, J. W., S. H. Park, D. Lavillette, F. L. Cosset, S. H. Yang, C. G. Lee, H. T. Jin, C. M. Kim, M. T. Shata, D. H. Lee, W. Pfahler, A. M. Prince, and Y. C. Sung. 2005. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42:1429-1436.
70. Yu, H., L. A. Babiuk, and S. van Drunen Littel-van den Hurk. 2004. Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J. Gen. Virol. 85:1533-1543.
71. + T-cell immune responses during chronic viral infection. J. Virol. 78:3578-3600.
72. Zhu, L. X., J. Liu, Y. Ye, Y. H. Xie, Y. Y. Kong, G. D. Li, and Y. Wang. 2004. A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World J. Gastroenterol. 10:2488-2492.